RGNT Company Profile and Key Details

Regentis Biomaterials Ltd. generated EPS of -$2.67 over the past year. Five-year average earnings growth is -71.58%.

Short-term trend indicators are bullishly aligned (SMA20 -15.58%, SMA50 -33.19%, SMA200 -34.87%). The stock’s 14-day RSI is 31.24 (weak momentum), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.63% below its high and over 6.89% above its low. Average 10-day trading volume of 3.44 thousand shares is below the 3-month average of 17.57 thousand, indicating normal recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Regentis Biomaterials Ltd. (AMEX:RGNT) closed at $3.10 USD, gaining $0.06 (1.97%) from the previous close of $3.04. The stock is currently mid-range between its 52-week high and low $2.80 and $8.35. With a market capitalization of about $12.21 million, Regentis Biomaterials Ltd. is classified as a micro-cap and shows market-like volatility (beta ~0.94). Key stats such as the average daily volume over the past year has been around 11.72 thousand shares, volume is running light vs its 52-week average. Headquartered in Herzliya, None, Regentis Biomaterials Ltd. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Ehud Geller, the company employs approximately 10 people and listed since September 11, 2025. Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions that restore the health and enhance quality of life of patients.

Regentis Biomaterials Ltd. (AMEX:RGNT) shares are flat 5.34% year-to-date currently trading near 52-week highs band. Our AI forecast model points to short-term strength (0.66% over two weeks), a medium-term fall (-97.04% over three months), and a longer-term loss (-99.67% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Regentis Biomaterials Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.66%, with price expected at $3.06 by April 28, 2026, within a range of $2.90 to $3.21 3-Month Outlook: Projected fall of -97.04%, reaching $0.09 by July 13, 2026, with a range of $0.03 to $0.16. 1-Year Outlook: Projected loss of -99.67%, with price at $0.01 by April 14, 2027, within a range of $0.00 to $0.08.